Intervacc is trading 15.93% down at €0.06 after broad biotech weakness and defensive risk reduction.
- The biotechnology sector fell 4.24% during the regular session.
- Broader markets weakened amid renewed inflation, geopolitical, oil-price, and bond-yield concerns.
- No fresh company-specific announcement was identified for September 1 or September 2, 2026; the latest official press-release coverage concerns an August 13 Strangvac regulatory filing.